Physician profile
David Sanchez
NPI 1316567928
$1,655.83
in general payments reported to CMS, 2019-2025
20 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $52.89 · 2024: $463 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $244.69 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $222.45 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $144.47 | 2024-2025 | |
| Pfizer INC. | $143.09 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $126.45 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $122.44 | 2024-2025 | Spravato |
| Abbvie INC. | $104.98 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.52 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $70.56 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $69.61 | 2023-2025 | Shingrix, Arexvy, Pediarix |
| Astellas Pharma US INC | $65.62 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.37 | 2024-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $37.24 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Inspire Medical Systems, INC. | $35.10 | 2024 | Inspire |
| Corcept Therapeutics | $29.69 | 2025 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.75 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $28.70 | 2025 | Nexletol |
| Eisai INC. | $27.93 | 2025 | |
| Sumitomo Pharma America, INC. | $18.54 | 2025 | Gemtesa |
| Shield Therapeutics INC | $13.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.